本文選題：美沙拉秦 + 蒙脫石散��； 參考：《中國免疫學(xué)雜志》2015年02期

【摘要】：目的:研究美沙拉秦、蒙脫石散、酪酸梭菌對2,4,6三硝基苯磺酸(TNBS)/乙醇法誘導(dǎo)的潰瘍性結(jié)腸炎大鼠IL-17、IL-23、TGF-β1、IFN-γ的影響。方法:將85只大鼠隨機分為模型組、美沙拉秦組、蒙脫石散組、酪酸梭菌組、美沙拉秦聯(lián)合蒙脫石散組5組,每組15只;正常大鼠為空白對照組10只,一共6組。通過TNBS/乙醇法建立潰瘍性結(jié)腸炎的大鼠模型。按大鼠體表面積折算藥量,分別給予相應(yīng)劑量生理鹽水、美沙拉秦、蒙脫石散、酪酸梭菌、美沙拉秦聯(lián)合蒙脫石散治療。12 d后處死全部大鼠,收集大鼠的血標(biāo)本及結(jié)腸標(biāo)本。采用ELISA法測定血清中IL-17、IL-23、TGF-β1、IFN-γ的含量,分別對比6組細胞因子的水平。結(jié)果:(1)通過TNBS/乙醇法建立大鼠模型,HE染色病理切片發(fā)現(xiàn)大鼠結(jié)腸遠端炎癥明顯。(2)模型組、美沙拉秦組、蒙脫石散組、酪酸梭菌組、美沙拉秦聯(lián)合蒙脫石散組較空白對照組的血清IL-17、IL-23和IFN-γ含量均升高,血清TGF-β1含量均降低,差異有統(tǒng)計學(xué)意義(P0.05)。(3)與模型組比較,蒙脫石散組、酪酸梭菌組、美沙拉秦組的血清IL-17、IL-23和IFN-γ含量均降低,血清TGF-β1含量均升高,差異有統(tǒng)計學(xué)意義(P0.05)。(4)美沙拉秦、蒙脫石散、酪酸梭菌和美沙拉秦聯(lián)合蒙脫石散的治療效果比較,美沙拉秦和美沙拉秦聯(lián)合蒙脫石散療效較好,差異有統(tǒng)計學(xué)意義(P0.05),酪酸梭菌與蒙脫石散療效差異不明顯。結(jié)論:(1)從癥狀體征及病理學(xué)檢查表明:TNBS/乙醇法成功建立了大鼠潰瘍性結(jié)腸炎模型。(2)在TNBS/乙醇法誘導(dǎo)的實驗性潰瘍性結(jié)腸炎大鼠血清中IL-17、IL-23、IFN-γ表達增高,與炎癥呈正相關(guān);結(jié)腸炎大鼠血清中TGF-β1表達降低,與炎癥呈負相關(guān)。(3)美沙拉秦、蒙脫石散、酪酸梭菌、美沙拉秦聯(lián)合蒙脫石散可能通過下調(diào)模型大鼠促炎因子IL-17、IL-23和調(diào)節(jié)因子IFN-γ的分泌,上調(diào)抗炎因子TGF-β1的分泌,緩解大鼠炎癥癥狀,利于大鼠潰瘍性結(jié)腸炎的修復(fù)。
[Abstract]:Aim: to study the effects of Mesalazin, montmorillonite powder and Clostridium caseate on IL-17 and IL-23 TGF- 尾 1 IFN- 緯 in rats with ulcerative colitis induced by TNBSU / ethanol. Methods: Eighty-five rats were randomly divided into three groups: model group, Mesalazin group, montmorillonite powder group, Clostridium caseinate group, Mesalazin combined with montmorillonite powder group with 15 rats in each group, and normal rats as blank control group (n = 10). The rat model of ulcerative colitis was established by TNBS/ ethanol method. The rats were given corresponding doses of normal saline, mesalazin, montmorillonite powder, Clostridium caseinate, Mesalazin combined with montmorillonite powder. All rats were killed after 12 days of treatment. Blood samples and colon specimens of the rats were collected. The serum levels of IL-17, IL-23, TGF- 尾 1, IFN- 緯 and cytokines were determined by ELISA method. Results (1) the rat model was established by TNBS/ ethanol method. The pathological sections of HE staining showed that the inflammation of distal colon was obvious in rats. (2) Model group, Mesalazin group, montmorillonite powder group, Clostridium caseinate group. Compared with the model group, the serum levels of IL-17, IL-23 and IFN- 緯 increased and the levels of serum TGF- 尾 1 decreased in the Mesalazin combined with montmorillonite powder group. The difference was statistically significant compared with the model group, the montmorillonite powder group and the Clostridium caseinate group. The serum levels of IL-17, IL-23 and IFN- 緯 decreased, and the levels of serum TGF- 尾 1 increased in the melalazin group. The difference was statistically significant (P 0.05. 05. 4) the therapeutic effects of Mesalazin, montmorillonite powder, Clostridium caseinate and melarazin combined with montmorillonite powder were compared. The curative effect of Mesalazin and Mesalazin combined with montmorillonite powder was better, the difference was statistically significant (P 0.05), but there was no significant difference between Clostridium caseinate and montmorillonite powder. Conclusion (1) the rat model of ulcerative colitis was successfully established by the TNBS/ ethanol method. (1) the expression of IL-17, IL-23, IFN- 緯 in the serum of rats with experimental ulcerative colitis induced by TNBS/ ethanol was increased, and the expression of IL-17 IL-23 IFN- 緯 was positively correlated with inflammation. The expression of TGF- 尾 1 in the serum of colitis rats was decreased, and negatively correlated with inflammation. The expression of Mesalazin, montmorillonite powder, Clostridium caseinate and Mesalazine combined with montmorillonite powder may be down-regulated by down-regulating the secretion of IL-17, IL-23 and IFN- 緯, the inflammatory factor IL-17 and the regulatory factor IFN- 緯 in rats with colitis. Upregulate the secretion of anti-inflammatory factor TGF- 尾 1, relieve the inflammatory symptoms of rats, and facilitate the repair of ulcerative colitis in rats.
【作者單位】： 大理白族自治州人民醫(yī)院兒科;昆明醫(yī)科大學(xué)第一附屬醫(yī)院兒科;昆明醫(yī)科大學(xué)附屬兒童醫(yī)院;
【基金】：益普生腹瀉基金資助項目(IDF-2012-01)
【分類號】：R574.62

【共引文獻】

相關(guān)期刊論文 前2條

1 馬鐵明;韓洋;馬賢德;曾曉霞;葛維;;不同灸量對潰瘍性結(jié)腸炎大鼠結(jié)腸上皮形態(tài)學(xué)及血清中炎性細胞因子、結(jié)腸組織中炎性細胞信號轉(zhuǎn)導(dǎo)通路的影響[J];針刺研究;2014年01期

2 鄭曉者;杜艷;;益生菌治療潰瘍性結(jié)腸炎的研究現(xiàn)狀[J];微生物學(xué)免疫學(xué)進展;2014年01期

相關(guān)會議論文 前1條

1 王燕;石劍;陳玲玲;;益生菌輔助治療潰瘍性結(jié)腸炎的臨床效果觀察[A];全國高血壓防治知識推廣培訓(xùn)班暨健康血壓中國行福建漳州會論文綜合刊[C];2014年

【相似文獻】

相關(guān)期刊論文 前10條

1 李登欣;宋光瑩;田強;;美沙拉秦治療潰瘍性結(jié)腸炎的臨床研究[J];濰坊醫(yī)學(xué)院學(xué)報;2006年03期

2 陳耀明;;美沙拉秦治療潰瘍性結(jié)腸炎的臨床研究[J];中國醫(yī)藥導(dǎo)報;2006年24期

3 肖軍華;鄭萍;黎文華;竇曉壇;康穎;;美沙拉秦聯(lián)合益生菌誘導(dǎo)緩解活動性潰瘍的臨床研究[J];現(xiàn)代生物醫(yī)學(xué)進展;2012年13期

4 張志會;;酪酸梭菌活菌膠囊聯(lián)合美沙拉秦治療潰瘍性結(jié)腸炎臨床觀察[J];長治醫(yī)學(xué)院學(xué)報;2012年02期

5 嚴(yán)紅;;美沙拉秦治療潰瘍性結(jié)腸炎療效觀察[J];井岡山學(xué)院學(xué)報(自然科學(xué)版);2006年01期

6 黃月華;李驥;趙淼;彭茜;任，

本文編號：1877618